medigraphic.com

2022, Number 1

<< Back Next >>

Rev Hematol Mex 2022; 23 (1)

Prognostic value of mutations in DNMT3A, TET2, IDH and IDH2 in acute myeloid leukemia

García-Solorio J, Cortés-Penagos C

Language: Spanish
References: 32
Page: 48-57
PDF size: 394.88 Kb.


ABSTRACT

Objective: To describe the prognostic value of mutations in the DNMT3A, TET2, IDH1 and IDH2 reported in the scientific literature and their coexistence with the markers that define acute myeloid leukemia entities according to the World Health Organization.
Methodology: Systematic review of scientific reports from journals with an impact factor greater than 2 in the period 2009 to 2021.
Results: The analysis of 1175 cases of acute myeloid leukemia with reported mutations in DNMT3A, TET2, IDH1 and IDH2 showed an association of 94.2% with the molecular marker NPM1. The coexistence of these mutations with balanced translocations was rare; however, some reports of coexistence with the chromosomal alterations t(8;21), inv16 and t(15;17) were found. Prognostic reports for these epigenetic markers were diverse for TET2, IDH1, and IDH2, while for DNMT3A was consistently adverse.
Conclusions: Changes in DNMT3A are common in NPM1-positive acute myeloid leukemia. According to the reports analyzed, this association implies a change in the prognosis of the disease, moving from a favorable condition to a poor prognosis.


REFERENCES

  1. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults.Lancet (London, England) 2013; 381 (9865): 484-95.

  2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, LeBeau MM, Bloomfield CD, Cazzola M, Vardiman JW. The2016 revision to the World Health Organization classificationof myeloid neoplasms and acute leukemia. Blood2016; 127 (20): 2391-405.

  3. Bullinger L, Krönke J, Schön C, Radtke I, Urlbauer K, BotzenhardtU, et al. Identification of acquired copy numberalterations and uniparental disomies in cytogeneticallynormal acute myeloid leukemia using high-resolutionsingle-nucleotide polymorphism analysis. Leukemia 2010;24 (2): 438-49.

  4. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, PaschkaP, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, etal. Genomic classification and prognosis in acute myeloidleukemia. N Engl J Med 2016; 374: 2209-2221.

  5. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, RobertsonA, et al. Genomic and epigenomic landscapes of adult denovo acute myeloid leukemia. N Engl J Med 2013; 368(22): 2059-74.

  6. Hou HA, Tien HF. Genomic landscape in acute myeloid leukemiaand its implications in risk classification and targetedtherapies. J Biomed Sci 2020; 27 (1): 81.

  7. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA,Bakhoum SF, et al. Clonal hematopoiesis and blood-cancerrisk inferred from blood DNA sequence. N Engl J Med 2014;371 (26): 2477-87.

  8. Steensma DP. Clinical implications of clonal hematopoiesis.Mayo Clin Proc 2018; 93 (8): 1122-30.

  9. Jaiswal S, Fontanillas P, Flannick J, Manning A, GraumanPV, Mar BG, et al. Age-related clonal hematopoiesis associatedwith adverse outcomes. N Engl J Med 2014; 371(26): 2488-98.

  10. Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E,et al. Genetic hierarchy and temporal variegation in theclonal history of acute myeloid leukaemia. Nat. Commun2016; 7: 12475.

  11. Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, ZehnderJL, et al. Next-generation sequencing of acute myeloidleukemia identifies the significance of TP53, U2AF1, ASXL1,and TET2 mutations. Mod Pathol 2015; 28: 706-14.

  12. Venney D, Mohd-Sarip A, Mills KI. The impact of epigeneticmodifications in myeloid malignancies. Int J Mol Sci 2021;22 (9): 5013.

  13. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, LarsonDE, et al. DNMT3A mutations in acute myeloid leukemia.N Engl J Med 2010; 363 (25): 2424-33.

  14. Weissmann S, Alpermann T, Grossmann V, Kowarsch A,Nadarajah N, Eder C, et al. Landscape of TET2 mutationsin acute myeloid leukemia. Leukemia 2012; 26 (5): 934-42.

  15. Boissel N, Nibourel O, Renneville A, Gardin C, Reman O,Contentin N, et al. Prognostic impact of isocitrate dehydrogenaseenzyme isoforms 1 and 2 mutations in acutemyeloid leukemia: a study by the Acute Leukemia FrenchAssociation group. J Clin Oncol 2010; 28: 3717-23.

  16. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K,Margeson D, et al. IDH1 and IDH2 gene mutations identifynovel molecular subsets within de novo cytogeneticallynormal acute myeloid leukemia: a Cancer and LeukemiaGroup B study. J Clin Oncol 2010; 28: 2348-55.

  17. Bezerra MF, Lima AS, Piqué-Borràs MR, Silveira DR,Coelho-Silva JL, Pereira-Martins DA, et al. Co-occurrenceof DNMT3A, NPM1, FLT3 mutations identifies a subset ofacute myeloid leukemia with adverse prognosis. Blood2020; 135 (11): 870-5.

  18. Dunlap JB, Leonard J, Rosenberg M, Cook R, Press R, FanG, et al. The combination of NPM1, DNMT3A, and IDH1/2mutations leads to inferior overall survival in AML. Am JHematol 2019; 94 (8): 913-20.

  19. Bezerra MF, Lima AS, Piqué-Borràs MR, Silveira DR,Coelho-Silva JL, Pereira-Martins DA, et al. Co-occurrenceof DNMT3A, NPM1, FLT3 mutations identifies a subset ofacute myeloid leukemia with adverse prognosis. Blood

  20. 2020; 135 (11): 870-5.20. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, RockovaV, Sanders M, Abbas S, et al. Mutant DNMT3A: a markerof poor prognosis in acute myeloid leukemia. Blood 2012;119 (24): 5824-31.

  21. Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3Amutation is a poor prognosis biomarker in AML: resultsof a meta-analysis of 4500 AML patients. Leuk Res 2013;37: 1445-50.

  22. Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, et al.DNMT3A R882 Mutation with FLT3-ITD positivity is anextremely poor prognostic factor in patients with normalkaryotypeacute myeloid leukemia after allogeneic hematopoieticcell transplantation. Biol Blood Marrow Transplant2016; 22 (1): 61-70.

  23. Wang R, Gao X, Yu L. The prognostic impact of tet oncogenefamily member 2 mutations in patients with acute myeloidleukemia: a systematic-review and meta-analysis. BMCCancer 2019; 19 (1): 389.

  24. Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne CH,Germing U, et al. TET2 mutations in acute myeloid leukemia(AML): results from a comprehensive genetic andclinical analysis of the AML study group. J Clin Oncol 2012;30 (12): 1350-7.

  25. Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1and IDH2 mutations: 2021 treatment algorithm. BloodCancer J 2021; 11 (6): 107.

  26. Cher CY, Leung GM, Au CH, Chan TL, Ma ES, Sim JP, et al.Next-generation sequencing with a myeloid gene panel incore-binding factor AML showed KIT activation loop andTET2 mutations predictive of outcome. Blood Cancer J2016; 6 (7): e442.

  27. Zhang Y, Wei H, Wang M, Huai L, Mi Y, Zhang Y, et al. Somenovel features of IDH1-mutated acute myeloid leukemia revealedin Chinese patients. Leuk Res 2011; 35 (10): 1301-6.

  28. Li W, Cui L, Gao C, Liu S, Zhao X, Zhang R, et al. DNMT3Amutations in Chinese childhood acute myeloid leukemia.Medicine (Baltimore) 2017; 96 (31): e7620.

  29. Yuan XQ, Chen P, Du YX, Zhu KW, Zhang DY, Yan H, et al.Influence of DNMT3A R882 mutations on AML prognosisdetermined by the allele ratio in Chinese patients. J TranslMed 2019; 17: 220.

  30. Eisfeld A, Mrózek K, Kohlschmidt J, Nicolet D, Orwick S,Walker C J, et al, & Bloomfield CD. The mutational oncoprintof recurrent cytogenetic abnormalities in adult patientswith de novo acute myeloid leukemia. Leukemia 2017;

  31. 31 (10): 2211-8.31. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, RockovaV, Sanders M, Abbas S, et al. Mutant DNMT3A: amarker of poor prognosis in acute myeloid leukemia. Blood2012;119(24):5824-31.

  32. Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3Amutation is a poor prognosis biomarker in AML: resultsof a meta-analysis of 4500 AML patients. Leuk Res 2013;37: 1445-50.




2020     |     www.medigraphic.com